MKMarina Kovelenova

Marina Kovelenova

*This is an algorithmically generated author record based on publicly available information.

Marina Kovelenova has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Threshold analysis of the patient’s route in infantile epileptic spasms syndrome: from the onset of spasms to first-line therapy

    by Elena V. Gumennik, A. V. Yatsenko, M. Yu. Fomina, D. D. Korostovtsev, M. V. Kovelenova, A. V. Markin, I. B. Sosnina, Yu. A. Yakovleva

    Background. Infantile epileptic spasms syndrome (IESS) is one of the most severe forms of early-onset epileptic encephalopathies and is associated with a high risk of pharmacoresistance, severe cognitive impairment, and premature mortality. Disease prognosis critically depends on the timeliness and adequacy of first-line therapy. Although delayed treatment of IESS is a universal problem, the specific stages of the patient care pathway at which delays occur may vary substantially depending on the organization of healthcare delivery. Aim. To identify key threshold stages of the patient care pathway and major barriers to timely initiation of rational therapy in children with IESS within the healthcare system of Saint Petersburg. Materials and methods. A retrospective observational study was conducted using the archive of the Epilepsy Clinic since 2018. A total of 130 children diagnosed with IESS according to International League Against Epilepsy criteria were included. Clinical and anamnestic data, magnetic resonance imaging findings, electroencephalography/video-electroencephalography monitoring results, and genetic testing data were analyzed. A threshold analysis of six consecutive stages of the patient care pathway was performed, from initial recognition of spasms to prescription of appropriate first-line therapy regimens. Early treatment response was assessed 2 weeks after therapy initiation Results. Developmental abnormalities prior to epileptic spasms onset were identified in 78 % of children; potentially epileptogenic magnetic resonance imaging abnormalities were found in 67 %. Causative genetic variants were detected in 18 % of the entire cohort. In 39 % of patients, the diagnosis was not established within the first month after spasm onset. In 96 (74 %) of 130 children, rational therapy was initiated more than one month after spasm onset. Six threshold points of potential treatment delay were identified. The main point of patient loss was late recognition of spasms at the stage of initial medical contact (loss of 27 out of 130 children). Moreover, delay at this stage deprived the child of any chance to receive timely therapy and constituted an insurmountable barrier to the subsequent steps of care. The second most important barrier was failure to initiate appropriate first-line therapy at treatment onset. The effectiveness of first-line therapy was more than 12-fold higher than that of standard antiseizure medications. Conclusion. Timely initiation of rational therapy in IESS is the result of passing through several consecutive threshold stages of the patient care pathway. The key systemic barriers in Saint Petersburg are late recognition of epileptic spasms and insufficient implementation of first-line therapy. These findings highlight the necessity of analyzing patient pathways within specific healthcare models and developing targeted programs for early detection and optimization of initial treatment.

  • Open Access

    Behavior and Speech Features of Children with ADHD

    by Elena Lyakso, Olga Frolova, Andrey Lebedev, Petr Shabanov, Severin Grechanyi, Elina Atamanova, Marina Kovelenova, Victoria Limarenko

    Background/Objectives: The goal of the study was to identify the peculiarities of attention deficit hyperactivity disorder (ADHD) on the base of the behavioral characteristics and acoustic features of speech of children with ADHD and ADHD with comorbidity—ADHD and autism spectrum disorders (ASD) and ADHD and intellectual disabilities (ID)—within the framework of one test task. Behavioral characteristics were selected using DSM-V criteria; acoustic features of speech were considered by researchers as speech markers of ASD and ID detected for different languages. Methods: The study includes 92 children aged 5–13 years with ADHD, ADHD and ID, ADHD and ASD, and control groups of children diagnosed with ASD, ID and typically developing (TD) children. The children were tested using the test task “co-op play”. Video and audio recordings of children performing the test task were collected. We used a complex approach to study the peculiarities of children with ADHD through expert analysis of children’s behavior and play, acoustic spectrographic analysis of speech and questionnaires about early childhood development filled out by parents. Results: The characteristics of behavior, play, and acoustic features of speech of children with ADHD and ADHD and comorbidity were revealed. Children with ADHD had lower behavior scores in the play situation on the expert assessment than TD children, with the greatest differences for characteristics of play, “Playing for toy”, and of behavior “Displaced activity” and “Losing attention”. The speech of children with ADHD is characterized by low values of the third formant and the difference between the first two formants, compared to the corresponding speech features of children from other groups. The speech of children with ADHD+ASD is characterized by maximal pitch values (high voice), while that of children with ADHD+ID is characterized by low vowel articulation index values. Conclusions: Based on the analysis of behavior and speech of children with TD, ADHD, ADHD and comorbidity performing the “co-op play” test task, the set of characteristics specific to ADHD was identified. The obtained data expand our understanding of the specificity of children with ADHD and may contribute to the development of qualified support for families with children with ADHD.


  • Cognitive effects of perampanel assessed by the EpiTrack Junior Test in school-aged children with epilepsy

    by E.V. Gumennik, M.YU. Bobylova, T.V. Sergeeva, D.YU. Butko, A.V. Yatsenko, M.YU. Fomina, Yu.A. Yakovleva, Yu.YU. Kalinina, M.V. Kovelenova, D.D. Korostovtsev, et al.

    Objective. To evaluate the impact of add-on perampanel on cognitive functions in school-aged children with epilepsy using the EpiTrack Junior test. Material and methods. Seventy-five patients aged 6—18 years were assessed before and 2 months after reaching a stable perampanel dose. They are divided into 2 groups according to the inclusion period (before 2023 and after 2023) due to the emergence of new literature data on the drug’s specific effectiveness in early adjuvant therapy after 2023. The 1st retrospective group consisted of 49 patients, most of whom were prescribed perampanel as a 4th—6th drug (54%). The 2nd prospective group consisted of 26 patients, most of whom (65%) were prescribed perampanel as a 2nd—3rd drug. Changes in total and subtest scores were analyzed versus diagnosis, sex, seizure-onset age, pharmacoresistance and EEG. Results. 66 patients completed the study. A significant increase in total EpiTrack score was observed (p<0.05) with positive correlation to seizure-onset age. Seizure reduction ≥50 % occurred in 68% and EEG improved in 40.9%. Reversible adverse events were reported in 25.8%. No statistically significant differences were found between the groups for any of these factors Conclusion. Adjunctive perampanel improves executive functions and is well tolerated in school-aged children with epilepsy.